-transparent.png){kind=logo}
The compatibility and stability at room temperature for up to 7 days of a three-drug admixture of cyclophosphamide, methotrexate, and 5-fluorouracil (5-FU) (CMF) was established permitting the practical delivery of the combination as an infusion in an ambulatory setting. Fourteen patients received 20 courses of CMF administered on a continuous infusion schedule for 14 days of a 28-day cycle. The dose rates were fixed for 5-FU (300 mg/M2/day) and methotrexate (0.75 mg/M2/day). The cyclophosphamide dose was escalated from 25 to 50, 75, and 100 mg/M2/d. Leukopenia and thrombocytopenia were observed in two of five patients receiving the maximal dose of cyclophosphamide. No other toxicities were observed including alopecia, stomatitis or liver function abnormalities. This Phase I trial suggests that the cumulative doses of cyclophosphamide, methotrexate, and 5-FU are comparable to the maximum doses delivered as single agent infusions. Furthermore, when the infusion CMF is compared to the "standard" bolus schedule for CMF, the infusion schedule delivers 116%, 8%, and 350% of the respective three component drugs (cyclophosphamide, methotrexate, and 5-FU).
J Lokich, and
M Bern, and
N Anderson, and
S Wallach, and
C Moore, and
K Beauchamp, and
D Williams
June 1991,
Anti-cancer drugs,
J Lokich, and
M Bern, and
N Anderson, and
S Wallach, and
C Moore, and
K Beauchamp, and
D Williams
November 1985,
Cancer,
J Lokich, and
M Bern, and
N Anderson, and
S Wallach, and
C Moore, and
K Beauchamp, and
D Williams
January 1983,
Cancer treatment reports,
J Lokich, and
M Bern, and
N Anderson, and
S Wallach, and
C Moore, and
K Beauchamp, and
D Williams
January 1995,
Cancer chemotherapy and pharmacology,
J Lokich, and
M Bern, and
N Anderson, and
S Wallach, and
C Moore, and
K Beauchamp, and
D Williams
October 1990,
American journal of clinical oncology,
J Lokich, and
M Bern, and
N Anderson, and
S Wallach, and
C Moore, and
K Beauchamp, and
D Williams
June 1998,
British journal of cancer,
J Lokich, and
M Bern, and
N Anderson, and
S Wallach, and
C Moore, and
K Beauchamp, and
D Williams
January 1984,
Anticancer research,
J Lokich, and
M Bern, and
N Anderson, and
S Wallach, and
C Moore, and
K Beauchamp, and
D Williams
January 1993,
Cancer chemotherapy and pharmacology,
J Lokich, and
M Bern, and
N Anderson, and
S Wallach, and
C Moore, and
K Beauchamp, and
D Williams
February 1986,
American journal of clinical oncology,
J Lokich, and
M Bern, and
N Anderson, and
S Wallach, and
C Moore, and
K Beauchamp, and
D Williams
January 1991,
Cancer chemotherapy and pharmacology,
